Public Health Emergency - Leading a Nation Prepared
Operational Intent: This performance measure examines how activities have been implemented to achieve the following outcomes
Required Program Performance Measure
What successes have you experienced regarding the continued planning, development, and implementation of a national system for special pathogen patient care using
RESPTC FY20 Administrative Supplement funds? What promising practices were developed/used to achieve that result? (Free response, 750-character response length)
Number of RESPTCs reporting success
Qualitative description of promising practices
What specific challenges or limitations have you encountered regarding your ability to plan, develop, and implement a national system for special pathogen care across sites? (Select all that apply)
Number of RESPTCs reporting each challenge
Which of the following strategies did your RESPTC employ to access and use NETEC information and resources usingRESPTC FY20 Administrative Supplement funds? (Select all that apply)
Utilized NETEC resources to improve operations and clinicaloutcomes within my RESPTC
Number of RESPTCs reporting challenges
**Note: A similar question appears in performance measures for the
RESPTC COVID-19 Preparedness and Response Activities Administrative Supplement. Please limit this particular response to activities and outcomes funded by the
RESPTC FY20 Administrative Supplement.
1 Funding for RESPTCs in FY20 built on previous Ebola programming, which specified this activity at the regional level. Due to the COVID-19 pandemic, ASPR sought to evolve the regional system already established through Ebola funding into a National Special Pathogens System (NSPS). In order to capture the true intent of RESPTCs’ role in this system, this document refers to a “national system for special pathogen patient care.” RESPTCs continue to operate regionally within this national system.
2 The Hospital Preparedness Program (HPP) Ebola Preparedness and Response Activities Cooperative Agreement (CFDA #93.817) Part B permits the Regional Ebola and Other Special Pathogen Treatment Centers to participate in clinical research, clinical trials, and experimental protocols, if appropriate, but recipients may not use cooperative agreement funds for research.
<< Previous ---------
Top of Page ---------
Home | Contact Us | Accessibility | Privacy Policies | Disclaimer | HHS Viewers & Players | HHS Plain Language | Vulnerability Disclosure Policy
Assistant Secretary for Preparedness and Response (ASPR), 200 Independence Ave., SW, Washington, DC 20201
U.S. Department of Health and Human Services | USA.gov |
HealthCare.gov in Other Languages